Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.
Biochem Biophys Res Commun. 2018 Mar 20;:
Authors: Xu DQ, Toyoda H, Qi L, Morimoto M, Hanaki R, Iwamoto S, Komada Y, Hirayama M
Abstract Mammalian target of rapamycin (mTOR) complex (mTORC) is frequently activated in diverse cancers. Although dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication.